Accueil   Diary - News   All news VALBIOTIS announces positive results from the Phase IIA clinical study of VALEDIA

VALBIOTIS announces positive results from the Phase IIA clinical study of VALEDIA

VALBIOTIS announces positive results from the Phase IIA clinical study of VALEDIA®, now the first product effective in people with prediabetes

 

  • VALEDIA® significantly reduced fasting and post-prandial blood glucose levels, two risk factors for types 2 diabetes, compared to placebo.
  • VALEDIA® significantly reduced body weight and waist circumference, compared to placebo
  • VALEDIA® is now the first clinically validated product designed for people woth prediabetes that reduces the risk factors for type 2 diabetes.

 

La Rochelle, 3 July 2019 (6:30 pm CEST) – VALBIOTIS (FR0013254851 – ALVAL PEA/SME eligible), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, today announced positive results (topline data) for the Phase IIA* study of VALEDIA® (active substance: TOTUM-63), which evaluated this product’s efficacy in a prediabetic population, compared to placebo.

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree